Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Neurofilament Surveillance Project (NSP)

NCT04516499 · View on ClinicalTrials.gov ↗

Study Summary

This is a biomarker study designed to collect and analyze blood specimens from individuals carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration" (ALLFTD) study, NCT04363684. More information can be found at https://www.allftd.org/.

Study Locations (8)

California

  • University of California, San Francisco — San Francisco

Florida

  • Mayo Clinic Florida — Jacksonville

Maryland

  • Johns Hopkins University School of Medicine — Baltimore

Massachusetts

  • Massachusetts General Hospital — Charlestown

Minnesota

  • Mayo Clinic — Rochester

Missouri

  • Washington University in St. Louis — St Louis

New York

  • Columbia University — New York

Pennsylvania

  • University of Pennsylvania — Philadelphia

Trial Details

FieldValue
Enrollment Target 342 participants
Start Date 2020-09-02
Est. Completion 2027-02

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04516499

The ClinicalTrials.gov registry entry for NCT04516499 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Bluefield Project to Cure Frontotemporal Dementia, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Frontotemporal Dementia appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04516499 reports 8 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04516499 about?

NCT04516499 is a clinical study titled "Neurofilament Surveillance Project (NSP)". This is a biomarker study designed to collect and analyze blood specimens from individuals carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to the ARTFL LEFFTDS Longit...

What is the current status of trial NCT04516499?

This trial is currently active not recruiting. The enrollment target is 342 participants. The study started on 2020-09-02. Estimated completion is 2027-02.

What conditions does trial NCT04516499 study?

This clinical trial studies the following conditions: Frontotemporal Dementia, Frontotemporal Lobar Degeneration, FTD, FTD-GRN, FTLD. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT04516499?

This trial is sponsored by The Bluefield Project to Cure Frontotemporal Dementia, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04516499 being conducted?

This trial has 8 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial